Evidence map›Paper›PMID 36222988›Full record

ReviewApplied biochemistry and biotechnology2023

SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.

Shubhra Khare, Niharika, Ajey Singh, Imtiyaz Hussain, Narsingh Bahadur Singh, Subhash Singh

Open access · bronzeAbstract readReview
In one paragraph

Review in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Shubhra KharePlant Physiology Laboratory, Department of Botany, University of Allahabad, Prayagraj, 211002, U.P., India.
NiharikaPlant Physiology Laboratory, Department of Botany, University of Allahabad, Prayagraj, 211002, U.P., India.
Ajey SinghDepartment of Botany, University of Lucknow, Lucknow, 226007, U.P., India.
Imtiyaz HussainGovernment Degree College, University of Ladakh, Dras, Ladakh, India.
Narsingh Bahadur SinghPlant Physiology Laboratory, Department of Botany, University of Allahabad, Prayagraj, 211002, U.P., India. singhnb166@gmail.com.ORCID http://orcid.org/0000-0001-6176-255X
Subhash SinghThe Institute of Optics, University of Rochester, Rochester, NY-14627, USA. ssingh49@ur.rochester.edu.
University of Allahabad · INUniversity of Lucknow · INUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current scenario of the coronavirus pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), considerable efforts have been made to control the pandemic by the development of a strong immune system through massive vaccination. Just after the discovery of the genetic sequences of SARS-CoV-2, the development of vaccines became the prime focus of scientists around the globe. About 200 SARS-CoV-2 candidate vaccines have already been entered into preclinical and clinical trials. Various traditional and novel approaches are being utilized as a broad range of platforms. Viral vector (replicating and non-replicating), nucleic acid (DNA and RNA), recombinant protein, virus-like particle, peptide, live attenuated virus, an inactivated virus approaches are the prominent attributes of the vaccine development. This review article includes the current knowledge about the platforms used for the development of different vaccines, their working principles, their efficacy, and the impacts of COVID-19 vaccines on thrombosis. We provide a detailed description of the vaccines that are already approved by administrative authorities. Moreover, various strategies utilized in the development of emerging vaccines that are in the trial phases along with their mode of delivery have been discussed along with their effect on thrombosis and gastrointestinal disorders.

Indexed as

COVID-19Gastrointestinal DiseasesThrombosisViral VaccinesCOVID-19 VaccinesHumansSARS-CoV-2COVID-19 VaccinesViral VaccinesGastrointestinal disordersNucleic acid vaccinePeptide vaccineSARS-CoV-2ThrombosisViral vector vaccineVirus vaccine

Identifiers

PMID36222988
PMCPMC9554396
OpenAlexW4304688701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.